Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,587 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Exhaled nitric oxide in chronic obstructive pulmonary disease.
Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Maziak W, et al. Among authors: sullivan p. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):998-1002. doi: 10.1164/ajrccm.157.3.97-05009. Am J Respir Crit Care Med. 1998. PMID: 9517624

Exhaled NO levels were significantly higher in patients with unstable COPD (12.7 +/- 1.5 ppb) than in other groups (p < 0.01). Exhaled NO levels were significantly higher in smokers with COPD than in smokers with chronic bronchitis (4.3 +/- 0.5 versus 2.5 +/- 0.5 ppb,

Exhaled NO levels were significantly higher in patients with unstable COPD (12.7 +/- 1.5 ppb) than in other groups (p < 0.01). Exh

Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics.
Jaffar ZH, Sullivan P, Page C, Costello J. Jaffar ZH, et al. Among authors: sullivan p. Eur Respir J. 1996 Mar;9(3):456-62. doi: 10.1183/09031936.96.09030456. Eur Respir J. 1996. PMID: 8730004 Clinical Trial.
Increased carbon monoxide in exhaled air of patients with cystic fibrosis.
Paredi P, Shah PL, Montuschi P, Sullivan P, Hodson ME, Kharitonov SA, Barnes PJ. Paredi P, et al. Among authors: sullivan p. Thorax. 1999 Oct;54(10):917-20. doi: 10.1136/thx.54.10.917. Thorax. 1999. PMID: 10491455 Free PMC article.
Normal subjects had higher NO levels (6.8 (0.4) ppb) than patients with cystic fibrosis (3.2 (0.2) ppb, mean difference 3.8 (95% CI 2.6 to 4.9), p<0.05) and were not influenced by steroid treatment (3.8 (0.4) ppb and 2.7 (0. 3) ppb for treated and untreated patients, re …
Normal subjects had higher NO levels (6.8 (0.4) ppb) than patients with cystic fibrosis (3.2 (0.2) ppb, mean difference 3.8 (95% CI 2.6 to 4 …
Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial.
Ramsay CF, Sullivan P, Gizycki M, Wang D, Swern AS, Barnes NC, Reiss TF, Jeffery PK. Ramsay CF, et al. Among authors: sullivan p. Respir Med. 2009 Jul;103(7):995-1003. doi: 10.1016/j.rmed.2009.01.019. Epub 2009 Feb 26. Respir Med. 2009. PMID: 19249198 Clinical Trial.
The zero-inflated Poisson statistical model demonstrated that montelukast significantly reduced post-treatment EG2+ cells by 80% compared with placebo (95% CI [70.6-86.8%]; P<0.0001). ...The reduction in mast cell numbers was 12% (95% CI [7.9, 16.0]; P<0.0001) …
The zero-inflated Poisson statistical model demonstrated that montelukast significantly reduced post-treatment EG2+ cells by 80% compared wi …
Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies.
Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P. Sullivan P, et al. Eur Respir J. 1998 Oct;12(4):811-5. doi: 10.1183/09031936.98.12040811. Eur Respir J. 1998. PMID: 9817150 Clinical Trial.
Effect of chronic theophylline treatment on the methacholine dose-response curve in allergic asthmatic subjects.
Page CP, Cotter T, Kilfeather S, Sullivan P, Spina D, Costello JF. Page CP, et al. Among authors: sullivan p. Eur Respir J. 1998 Jul;12(1):24-9. doi: 10.1183/09031936.98.12010024. Eur Respir J. 1998. PMID: 9701409 Clinical Trial.
The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects.
Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH. Harbinson PL, et al. Among authors: sullivan pj. Eur Respir J. 1997 May;10(5):1008-14. doi: 10.1183/09031936.97.10051008. Eur Respir J. 1997. PMID: 9163639 Clinical Trial.
The late asthmatic response (LAR) to allergen, expressed as area under the curve at 3-8 h (AUC3-8h), was inhibited by 30% (p=0.016), an effect which persisted to the end of the observation period. ...
The late asthmatic response (LAR) to allergen, expressed as area under the curve at 3-8 h (AUC3-8h), was inhibited by 30% (p=0.016), …
Platelet dynamics following allergen challenge in allergic asthmatics.
Sullivan PJ, Jafar ZH, Harbinson PL, Restrick LJ, Costello JF, Page CP. Sullivan PJ, et al. Respiration. 2000;67(5):514-7. doi: 10.1159/000067466. Respiration. 2000. PMID: 11070455 Clinical Trial.
Anti-inflammatory effects of low-dose oral theophylline in atopic asthma.
Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Sullivan P, et al. Lancet. 1994 Apr 23;343(8904):1006-8. doi: 10.1016/s0140-6736(94)90127-9. Lancet. 1994. PMID: 7909049 Clinical Trial.

After treatment with theophylline there was a significant reduction in the number of EG2-positive activated eosinophils (5.9 before and 2.1 after treatment, Wilcoxon signed rank p < 0.05) and total eosinophils (16.7 before and 7.6 after treatment, p < 0.05) be

After treatment with theophylline there was a significant reduction in the number of EG2-positive activated eosinophils (5.9 before and 2.1 …
Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose-finding study.
Badner NH, Reid D, Sullivan P, Ganapathy S, Crosby ET, McKenna J, Lui A. Badner NH, et al. Among authors: sullivan p. Can J Anaesth. 1996 Jan;43(1):17-22. doi: 10.1007/BF03015952. Can J Anaesth. 1996. PMID: 8665629 Clinical Trial.

The ropivacaine 0.1%, 0.2%, 0.3% groups required less morphine over the 21 hr than the saline group (P < 0.01). The VAS pain scores were also lower in the three ropivacaine groups (P < 0.001). The ropivacaine groups maintained sensory anaesthesia to pinprick w

The ropivacaine 0.1%, 0.2%, 0.3% groups required less morphine over the 21 hr than the saline group (P < 0.01). The VAS pain score

2,587 results
Jump to page
Feedback